The burgeoning landscape of therapeutic interventions for metabolic disorders has witnessed considerable attention focused on GLP-3 analogues and, more recently, the dual GIP and GLP-3 agonist retatrutide. While both https://maciezxrc887284.ja-blog.com/39283490/glp-3-retatrutide-a-comparative-analysis